Overview of the drug development pipeline for the atypical hemolytic uremic syndrome
It has been observed that atypical hemolytic uremic syndrome (aHUS) is a systematic disease that is characterized by adverse impacts on the functions of the kidneys in the human body. This rare condition is associated with genetic mutations or polymorphisms that result in chronic, uncontrolled activation of the alternative complement pathway. This syndrome is characterized by three major problem areas which are - progressive renal failure, problems associated with red blood cell and platelet counts, and problems that occur with the vascular system.
Atypical HUS is not caused by any external agents like bacteria or virus, and this disorder is triggered by some internal chain of events. In the US, the incidence of aHUS is estimated to be one in 500,000 people per year. Several public and private companies are focused on the development of drug molecules for the treatment and diagnosis of aHUS. Monotherapy is emerging as the most efficient approach for the treatment of aHUS.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of the atypical hemolytic uremic syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Pipeline analysis report on drug development for aHUS: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of aHUS. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Achhilion Pharmaceuticals
- Akari Therapeutics
- Alexion
Therapeutic assessment of the drug development pipeline for atypical hemolytic uremic syndrome by route of administration
- Subcutaneous
- Oral
- Intravenous + subcutaneous
- Intravenous
- Undisclosed
The subcutaneous route of administration (ROA) involves the administration of the drug directly into the layer of the skin below the dermis and the epidermis, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for atypical hemolytic uremic syndrome by therapy
- Monotherapy
According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for atypical hemolytic uremic syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug therapy molecules in the various development stages for atypical hemolytic uremic syndrome?
- What are the companies that are currently involved in the development of drug molecules for atypical hemolytic uremic syndrome?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.